Fig. 2: Clinical trial design and survival outcomes. | Nature Communications

Fig. 2: Clinical trial design and survival outcomes.

From: Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort

Fig. 2

Patients in the first stage of this clinical trial (S1) were randomized to no treatment prior to surgical resection of recurrent glioblastoma (Adjuvant cohort, S1, blue) or single dose of pembrolizumab 200 mg prior to surgery (Neoadjuvant cohort, S1, red). An additional 25 patients were enrolled in a second stage as a neoadjuvant expansion cohort (Neoadjuvant cohort, S2, black). a Clinical trial schema. b Kaplan–Meier plot of overall survival in the modified intention-to-treat population. Median survival of the neoadjuvant expansion cohort (black) was 209.5 days, compared to 400 days in the stage 1 neoadjuvant cohort (red) and 192 days in the stage 1 adjuvant cohort (blue) (p = 0.0858 logrank test). c Kaplan–Meier plot of progression-free survival in the modified intention-to-treat population. Median progression-free survival of the neoadjuvant expansion cohort (black) was 75 days, compared to 99.5 days in the stage 1 neoadjuvant cohort (red) and 72.5 days in the stage 1 adjuvant cohort (blue) (p = 0.0543 logrank test). Source data are provided as a Source Data file.

Back to article page